Table 2.
Clinical parameters of the control and test groups at baseline, 4 weeks, and 8 weeks (mean ± SD)
| Clinical parameters | Control (N = 45) | Test (N = 48) | p-value* |
|---|---|---|---|
| GI | 0.042 | ||
| Baseline | 1.00 ± 0.46 | 1.19 ± 0.51 | |
| 4 weeks | 1.01 ± 0.46 | 1.02 ± 0.44† | |
| 8 weeks | 0.90 ± 0.50 | 0.95 ± 0.49† | |
| Δ baseline – 4 weeks | 0.01 ± 0.38 | −0.18 ± 0.33‡ | |
| Δ baseline – 8 weeks | −0.10 ± 0.40 | −0.24 ± 0.38 | |
| PI | 0.138 | ||
| Baseline | 1.50 ± 0.68 | 1.61 ± 0.67 | |
| 4 weeks | 1.45 ± 0.68 | 1.55 ± 0.58 | |
| 8 weeks | 1.48 ± 0.61 | 1.42 ± 0.52† | |
| Δ baseline – 4 weeks | − 0.05 ± 0.40 | −0.06 ± 0.48 | |
| Δ baseline – 8 weeks | − 0.02 ± 0.39 | −0.18 ± 0.52 | |
| PD | 0.381 | ||
| Baseline | 2.49 ± 0.39 | 2.63 ± 0.47 | |
| 4 weeks | 2.47 ± 0.37 | 2.52 ± 0.49† | |
| 8 weeks | 2.39 ± 0.36 | 2.51 ± 0.51† | |
| Δ baseline – 4 weeks | − 0.02 ± 0.25 | −0.11 ± 0.29 | |
| Δ baseline – 8 weeks | − 0.10 ± 0.36 | −0.11 ± 0.34 | |
| CAL | 0.571 | ||
| Baseline | 2.74 ± 0.69 | 2.76 ± 0.87 | |
| 4 weeks | 2.75 ± 0.66 | 2.69 ± 0.84 | |
| 8 weeks | 2.72 ± 0.71 | 2.72 ± 0.88 | |
| Δ baseline – 4 weeks | 0.01 ± 0.31 | −0.07 ± 0.42 | |
| Δ baseline – 8 weeks | − 0.02 ± 0.46 | −0.03 ± 0.48 | |
| 100 mm VAS | 0.059 | ||
| Baseline | 17.38 ± 16.69 | 18.46 ± 18.86 | |
| 4 weeks | 13.42 ± 18.72† | 11.17 ± 13.68† | |
| 8 weeks | 12.64 ± 16.90† | 4.94 ± 6.34†‡ | |
| Δ baseline – 4 weeks | −3.96 ± 21.45 | −7.29 ± 17.55 | |
| Δ baseline – 8 weeks | −4.73 ± 19.80 | −13.52 ± 17.71 | |
GI gingival index, PI plaque index, PD probing depth, CAL clinical attachment level, VAS visual analog scale
*Difference in the change of each parameter during 8 weeks between the groups using repeated measures ANOVA (p < 0.05)
†Statistically significant difference compared to the baseline within each group using Wilcoxon Signed Ranks Test (p < 0.05)
‡Statistically significant difference between the groups using Mann-Whitney U test (p < 0.05)